Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 7, 2004, Pages 1182-1183

  Zotz, Rainer B ^a   Gerhardt, A ^a   Scharf, R E ^a   Brenner, B ^b   Martinelli, I ^c   Walker, Isobel D ^d   Grandone, E ^e,f   Margaglione, M ^e,f   Wells, P S ^g,h   Rodger, M A ^g   Conard, Jacqueline ⁱ  

^a UNIVERSITY OF COLOGNE   (Germany)

^b RAMBAM MEDICAL CENTER   (Israel)

^c UNIVERSITY OF MILAN   (Italy)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f UNIVERSITY OF FOGGIA   (Italy)

^g OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^h Hotel Dieu University Hospital ^*  (Canada)

ⁱ HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENINE; BLOOD CLOTTING FACTOR 5 LEIDEN; ENOXAPARIN; GUANINE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PLACEBO; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG INDICATION; FAMILY STUDY; HOMOZYGOSITY; HUMAN; INHERITANCE; LUNG EMBOLISM; MEDICAL DECISION MAKING; META ANALYSIS; METHODOLOGY; OSTEOPOROSIS; PATIENT MONITORING; PATIENT SELECTION; PREDICTION; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RECURRENT ABORTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOPHILIA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 19944432145     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00823.x     Document Type: Article

References (86)

1. Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - No. J Thromb Haemost 2003; 1: 2073-4.
2. Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - Yes. J Thromb Haemost 2003; 1: 2070-2.
3. Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003; 90: 77-85.
4. Middeldorp S, Libourel EJ, Hamulyak K, van der Meer J, Buller HR. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 2001; 113: 553-5.
5. Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001; 86: 800-3.
6. Zotz RB, Gerhardt A, Scharf RE. Inherited thrombophilia and gestational venous thromboembolism. Best practice and research in clinical hematology. Best Pract Res Clin Haematol 2003; 16: 243-59.
7. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-8.
8. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan JS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, MacGillavry MR, Hamulyak K, Theunissen IM, Hunt BJ, Buller HR. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-72.
9. Middeldorp S. Anti-thrombotic prophylaxis for women with thrombophilia and pregnancy complications - No. J Thromb Haemost 2003; 1: 2073-4.
10. Brenner B. Antithrombotic prophylaxis women with thrombophilia in pregnancy complications - Yes. J Thromb Haemost 2003; 1: 2070-2.
11. Sarto A, Martinez M, Falco A, Smaltino V, Mulki O, Marazzi A, Paganini A, Pasqualini S. Preconceptional and gestational enoxaparin regimes adjusted to fertility program to prevent preclinical, embyonic and fetal loss in women with recurrent pregnancy loss (RPL) and thrombophilia. Thromb Haemost in press.
12. Brenner B, Hoffman R., Carp H, Dulitsky M, Samuelov A, Yohai D, Bar Y, Thaler I, Yarom I, Ellis M, Varon D, Tal Y, Blumenfeld Z, Segal S, Kupferminc M, Younis J for the LIVE-ENOX Investigators. Efficacy and safety of enoxaparin for improving pregnancy outcomes in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX Study. Blood 2003; 102: 16a (Abstract).
13. Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Neveu S, Tailland ML, Dauzat M, Mares P. Low molecular weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-9.
14. Brenner B. Clinical management of thrombophilia related placental vascular complications. Blood 2004; 103: 4003-9.
15. Brenner B. Thrombophilia and fetal loss. Semin Thromb Haemost 2003; 29: 165-70.
16. Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - Yes. J Thromb Haemost 2003; 1: 2070-2.
17. Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - No. J Thromb Haemost 2003; 1: 2073-4.
18. Rai R, Cohen H, Dave M, Regan L. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-7.
19. Martinelli I, Taioli E, Cetin I, Mannucci PM. Recurrent late fetal death in women with and without thrombophilia. Thromb Haemost 2002; 87: 358-9.
20. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.
21. Kupferminc MJ, Fait J, Many A, Lessing JB, Yair D, Bar-Am A, Eldor A. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 2001; 20: 35-44.
22. Vossen C, Conard J, Fontcuberta J, De Jonge I, Makris M, van der Meer F, Pabinger I, Palareti G, Preston F, Scharrer I, Souto J, Svensson P, Walker I, Rosendaal F. Thromboprophylaxis reduces the risk of fetal loss in women with hereditary thrombophlia. Blood 2002; 100: 273a.
23. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119: 122S-131S.
24. Martinelli I. Pros and cons of thrombophilia screening: pros. J Thromb Haemost 2003; 1: 410-1.
25. Brenner B. Maternal anticoagulant prophylaxis for prevention of pregnancy loss in women with thrombophilia - yes. J Thromb Haemost 2003; 1: 416-7.
26. Bonnar J. Can more be done in obstetric and gynecologic practice to reduce morbidity and mortality associated with venous thromboembolism? Am J Obstet Gynecol 1999; 180: 784-91.
27. Gates S. Thromboembolic disease in pregnancy. Current Opinion Obstetrics Gynecol 2000; 12: 117-22.
28. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet, 2003; 361: 901-8.
29. Cohen H. Randomized trial of aspirin versus aspirin and heparin in pregnant women with the antiphospholipid syndrome. Ann Med Interne 1996; 147 (Suppl. 1): 44.
30. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment [erratum appears in Obstet Gynecol 2002; 100: 1361]. Obstet Gynecol 2002; 100: 408-13.
31. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-9.
32. Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 1996; 35: 402-7.
33. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-7.
34. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.
35. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003; 1: 433-8.
36. Sanson B-J, Lensing AWA, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, Mac Gillavry MR, Hamulyak K, Theunissen IM, Hunt BJ, Buller HR. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-72.
37. Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, Priollet P, Cohen C, Yvelin N, Schved JF, Tournaire M, Borg JY. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obs Gynaecol 2001; 108: 1134-40.
38. Howell R, Fidler J, Letsky E, De Swiet M. The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. Br J Obs Gynaecol 1983; 90: 1124-8.
39. Hill NC, Hill JG, Sargent JM, Taylor CG, Bush PV. Effect of low dose heparin on blood loss at caesarean section. Br Med J (Clin Res Edn) 1988; 296: 1505-6.
40. Heilmann L, Heitz R, Koch FU, Ose C. Perioperative prevention of thrombosis in cesarean section: results of a randomized prospective comparative study with 6% hydroxyethyl starch and 0.62 low dose heparin. Z Geburtshilfe Perinatol 1991; 195: 10-15.
41. Krauss T, Rath W, Dittmer U, Kuhn W. Prevention of thromboembolism with low molecular weight heparin (Fragmin) in obstetrics. Z Geburtshilfe Perinatol 1994; 198: 120-5.
42. Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - No. J Thromb Haemost 2003; 1: 417-8.
43. Regan L, Braude PR, Trembath PL. Influence of past reproductive performance on risk of spontaneous abortion. Br Med J 1989; 299: 541-5.
44. Stirrat GM. Recurrent miscarriage. I. Definition and epidemiology. Lancet 1990; 336: 673-5.
45. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31.
46. Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002; 99: 333-41.
47. Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss. Arch Intern Med 2004; 164: 558-63.
48. Duley L. Aspirin for preventing and treating pre-eclampsia. BMJ 1999; 318: 751-2.
49. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119: 122S-131S.
50. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.
51. Grandone E, Brancaccio V, Colaizzo D, Scianname' N, Pavone G, Di Minno G, Margaglione M. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 2002; 78: 371-5.
52. Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complication - No. J Thromb Haemost 2003; 1: 2073-4.
53. Brenner B, Hoffman R, Carp H, Dulitsky M, Samueloff A, Yohal D, Bar Y, Thaler I, Yarom, I, Ellis M, Varon D, Tal Y, Blumenfeld Z, Segal S, Kupferminc M, Younis J, LIVE-ENOX INVESTIGATORS. Efficacy and Safety of Two Doses of Enoxaparin in Pregnant Women with Thrombophilia and Recurrent Pregnancy Loss: the Live-Enox Study. OC084, ISTH 2003. J Thromb Haemost 2003; 1 (Suppl 1).
54. Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - yes. J Thromb Haemost 2003; 1: 2070-2.
55. Rodger MA, Makropoulos D, Walker MC, Keely EJ, Karovitch AJ, Wells PS. Participation of pregnant women in clinical trials: will they participate and why? Am J Perinatol 2003; 20: 69-76.
56. Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - Yes. J Thromb Haemost 2003; 1: 2070-2.
57. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.
58. Sacks HS, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials. Am J Med 1982; 72: 233-40.
59. Brenner B, Hoffman R, Carp H, Dulitsky M, Samueloff A, Yohai D, Bar Y, Thaler I, Yarom I, Ellis M, Varon D, Tal Y, Blumenfeld Z, Segal S, Kupferminc M, Younis J. Enoxaparin treatment improves the gestational outcome of pregnant women with thrombophilia and recurrent pregnancy loss: The LIVE-ENOX Study. Blood 2003; 102: 16a (abstract 43).
60. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003; 1: 433-8.
61. Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - No. J Thromb Haemost 2003; 1: 2073-4.
62. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-7.
63. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408-13.
64. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-9.
65. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000; 183: 1008-12.
66. Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, Priollet P, Cohen C, Yvelin N, Schved JF, Tournaire M, Borg JY. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol 2001; 108: 1134-40.
67. Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake S, Buchanan N, Hughes G, Khamashta M. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77: 39-43.
68. de Raucourt E, Vinsonneau C, Juvin K, Fischer AM, Meyer G. Heparin-induced thrombocytopenia with thrombotic complications during prophylactic treatment with low-molecular-weight heparin. Blood Coagul Fibrinolysis 1996; 7: 786-8.
69. Elalamy I, Potevin F, Lecrubier C, Bara L, Marie JP, Samama MM. A fatal low-molecular-weight heparin-associated thrombocytopenia after hip surgery: possible usefulness of PF4-heparin ELISA test. Blood Coagul Fibrinolysis 1996; 7: 665-71.
70. Horlocker TT, Wedel DJ. Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998; 23: 164-77.
71. Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - yes. J Thromb Haemost 2003; 1: 2070-2.
72. Middledorp, S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - no. J Thromb Haemost 2003; 1: 2073-4.
73. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63: 319-20.
74. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C and protein S deficiency. Arterioscl Thromb Vasc Biol 1996; 16: 742-8.
75. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, Gavasso S, Huisman MV, Buller HR, ten Cate JW, Girolami A, Prins MH. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1998; 81: 198-202.
76. Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, Prandoni P, Buller HR, Girolami A, Prins MH. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125: 955-60.
77. Ginsberg JS, Greer IA, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119 (Suppl.): 122S-31S.
78. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-65.
79. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the the period of risk and the leg of presentation. Obstet Gynecol Survey 1999; 54: 265-71.
80. Tincani A, Branch W, Levy RA, Piette JC, Carp H, Rai RS, Khamashta M, Shoenfeld Y. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003; 12: 524-9.
81. Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-23.
82. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? Eur J Obstet Gynecol Reprod Biol 2002; 101: 6-14.
83. Roque H, Paidas MJ, Funai EF, Kuczynski E, Lockwood CJ. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004; 91: 290-5.
84. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RV. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-12.
85. Carp H, Dolitzky M, Inbal L. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003; 1: 433-8.
86. Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, Priollet P, Cohen C, Yvelin N, Schved JF, Tournaire M, Borg JY. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol 2001; 108: 1134-1.